Carfentanil

This page covers what carfentanil is, how its potency compares with other opioids, and what its presence in the drug supply means for overdose response.

Key Takeaways

• Carfentanil is approximately 100 times more potent than fentanyl and approximately 10,000 times more potent than morphine, according to the US Drug Enforcement Administration.
• Carfentanil has no approved human medical use. Its only legitimate application is veterinary immobilization of large animals.
• Overdoses involving carfentanil frequently require multiple naloxone doses, because carfentanil binds tightly to the mu-opioid receptor and dissociates slowly.
• A single naloxone dose that produces no response is not evidence that opioids were not involved.
• Carfentanil appears in the drug supply intermittently and regionally rather than continuously, which is why local overdose spikes are the usual first signal of its presence.

What is carfentanil?

Carfentanil is a synthetic opioid of the fentanyl analogue family, developed as a veterinary immobilizing agent for large animals. It acts on the same mu-opioid receptors as every other opioid and has no approved therapeutic use in humans anywhere in the United States.

Carfentanil matters to the public not as a drug people seek but as a contaminant they encounter. It appears intermittently in the unregulated opioid supply, and its arrival in a local supply changes what an overdose looks like to the people responding to it and what reversing that overdose requires. This page does not cover the signs of opioid use, the effects of opioids on the body or the course of opioid withdrawal, which are the same for carfentanil as for any other opioid.

Its legitimate role is narrow and specialized. Carfentanil is used by veterinarians and wildlife professionals to sedate animals whose body mass makes ordinary anesthetics impractical, which is why it is frequently described in press coverage as an elephant tranquiliser. That description is accurate about its purpose and misleading about its danger, since the reason it works on an elephant is potency rather than any species-specific property.

Carfentanil reaches people through the unregulated drug supply, where it is used as an adulterant. The US Drug Enforcement Administration issued a public safety alert about carfentanil in September 2016. The Centers for Disease Control and Prevention documented its role in overdose clusters in its Carfentanil Outbreak, Florida, 2016-2017 report published in the Morbidity and Mortality Weekly Report in 2020.

Carfentanil produces the same effects, the same dependence and the same withdrawal as every other opioid, because it acts on the same receptor. Those are covered on the page on opioid addiction, its signs, effects and withdrawal and are not repeated here. What is specific to carfentanil is potency.

Understanding why a contaminant of this kind is so consequential requires understanding where it sits on the potency scale.

How potent is carfentanil compared with fentanyl and morphine?

Carfentanil is approximately 100 times more potent than fentanyl and approximately 10,000 times more potent than morphine. Fentanyl is itself approximately 50 times more potent than heroin, which places carfentanil several orders of magnitude beyond the opioids the drug supply was built around.

The following comparisons are the relative potency figures published by the US Drug Enforcement Administration and corroborated by the CDC.

Potency is not the same as toxicity, and the distinction matters for understanding the risk correctly. Potency describes how much substance is needed to produce a given effect. Carfentanil is not more poisonous than morphine at equivalent effect. It reaches that effect, including the respiratory depression that kills, at a quantity vastly smaller than any other opioid in circulation.

The practical consequence is that the tolerances the illicit supply operates within cease to function. Mixing and dilution carried out by hand cannot distribute a substance of this potency evenly, so the variation between one portion and the next becomes the dominant risk factor. This is the same uneven-distribution problem described on the page on fentanyl and why it is so dangerous, scaled up by two orders of magnitude.

That scaling is also what changes the arithmetic of reversal.

Why do carfentanil overdoses often need repeated naloxone doses?

Carfentanil overdoses frequently require repeated naloxone doses because carfentanil binds tightly to the mu-opioid receptor and dissociates from it slowly. Naloxone works by competing for that receptor, and a slowly dissociating opioid resists displacement by a single standard dose.

Naloxone is a competitive antagonist. It reverses an opioid overdose by occupying mu-opioid receptors and pushing the opioid off them, which restores respiratory drive. The success of that competition depends on how readily the opioid lets go. Research on fentanyl analogues has found that slow dissociation from the receptor correlates with reduced sensitivity to naloxone reversal, and carfentanil sits at the extreme end of that behavior.

Two operational consequences follow, and both are the reason this page exists:

• Repeat dosing is expected rather than exceptional. Naloxone is given every 2 to 3 minutes until the person breathes independently or emergency services take over.
• Re-sedation is a genuine risk. Naloxone has a shorter duration of action than carfentanil, so a person who responds can stop breathing again once the naloxone wears off. This is why the person must not be left alone after a reversal.

Neither point changes the instruction to give naloxone. Naloxone remains the correct response to any suspected opioid overdose, and there is no harm in giving it to someone whose collapse turns out not to be opioid-related. Practical administration guidance is on the page on Narcan and naloxone.

What does carfentanil in the drug supply mean for overdose response?

Carfentanil in a local supply means overdose clusters appear suddenly, standard naloxone quantities prove insufficient, and the people affected have usually not chosen to take carfentanil. Response depends on wider naloxone availability, rapid public warning and someone being present to act.

Carfentanil enters the supply episodically and regionally rather than as a steady presence. Its arrival therefore registers first as an unexplained spike in overdoses within a specific area over a short period. Public health surveillance systems are built to detect exactly this pattern, and the CDC's Florida outbreak report documented that sequence.

The population at risk is not defined by intent. People who die in carfentanil-involved overdoses have generally bought something else, which places anyone using an unregulated opioid supply within the exposed group regardless of experience, tolerance or caution. That is the same dynamic driving fentanyl deaths, with an even smaller margin.

Three measures shape the outcome once carfentanil is present in a community:

• Carrying naloxone, and carrying more than one dose
• Never using alone, so that someone is present to call 911 and administer it
• Attending to local public health alerts, which is how most people learn a supply has changed

Montana distributed over 78,000 naloxone kits in 2023, according to the Montana Department of Public Health and Human Services.

Two investigational approaches target the reversal problem carfentanil creates. The FDA approved nalmefene nasal spray in May 2023, and Nallani and colleagues set out its longer duration of action, which matters when the opioid outlasts naloxone. Bremer and colleagues reported that the fentanyl-specific monoclonal antibody CSX-1004 binds the drug before it reaches the receptor, and it has reached phase 1 testing in humans. Neither is approved for carfentanil specifically.

Withdrawal that follows a reversal is scored the same way as any opioid withdrawal. Clinicians use the Clinical Opiate Withdrawal Scale (COWS), an 11-item instrument developed by Wesson and Ling that rates pulse, sweating, pupil size, gooseflesh and further signs to guide treatment.

None of these measures treats opioid use disorder. They keep a person alive through the period in which the disorder remains untreated, which is the precondition for anything else.

Frequently asked questions

Sources

1. US Drug Enforcement Administration. Public safety alert on carfentanil, 22 September 2016. Relative potency of carfentanil against fentanyl and morphine, absence of human therapeutic use, and naloxone dosing requirements.
2. Centers for Disease Control and Prevention (2020). Carfentanil Outbreak, Florida, 2016-2017, Morbidity and Mortality Weekly Report, Volume 69, Number 5. Outbreak pattern and toxicological confirmation.
3. Centers for Disease Control and Prevention. Notes from the Field: Overdose Deaths with Carfentanil and Other Fentanyl Analogs Detected, 10 States, July 2016 to June 2017, Morbidity and Mortality Weekly Report. Geographic and episodic distribution.
4. Montana Department of Public Health and Human Services (2025). Opioid Use in Montana. Statewide naloxone distribution figures.
5. Nallani, S. C. et al. (2025). FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose, Clinical Pharmacology and Therapeutics, 117(3), 620-626. Approval basis and pharmacology of the 2023 nalmefene approval.
6. Bremer, P. T. et al. (2023). Investigation of monoclonal antibody CSX-1004 for fentanyl overdose, Nature Communications, 14, 7700. Early-phase data on fentanyl-specific monoclonal antibodies.
7. Wesson, Donald R. and Ling, Walter (2003). The Clinical Opiate Withdrawal Scale (COWS), Journal of Psychoactive Drugs, 35(2), 253-259. Eleven-item scoring of opioid withdrawal severity.